The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations
Open accessAbstract
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by circulating autoantibodies and the formation of immune complexes. In these responses, the selecting self-antigens likely derive from the remains of dead and dying cells, as well as from disturbances in clearance. During cell death/activation, microparticles (MPs) can be released to the circulation. Previous MP studies in SLE have been limited in size and differ regarding numbers and phenotypes. Therefore, to characterize MPs more completely, we investigated 280 SLE patients and 280 individually matched controls. MPs were measured with flow cytometry and phenotyped according to phosphatidylserine expression (PS+/PS−), cellular origin and inflammatory markers. MPs, regardless of phenotype, are 2–10 times more abundant in SLE blood compared to controls. PS− MPs predominated in SLE, but not in controls (66% vs. 42%). Selectively in SLE, PS− MPs were more numerous in females and smokers. MP numbers decreased with declining renal function, but no clear association with disease activity was observed. The striking abundance of MPs, especially PS− MPs, suggests a generalized disturbance in SLE. MPs may be regarded as “liquid biopsies” to assess the production and clearance of dead, dying and activated cells, i.e. pivotal events for SLE pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Moreover, patients with higher disease activity have notably higher numbers of extracellular vesicle-containing immune complexes with exposed mitochondrial outer membrane markers, TOMM-20 and hexokinase I218, than patients with lower disease activity, suggesting that proteins of mitochondrial origin could be potential autoantigens in SLE217.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [217]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The plasma of patients with SLE contains elevated levels of extracellular vesicle-containing immune complexes compared with healthy individuals, the presence of which is associated with anti-dsDNA antibodies, pro-inflammatory cytokines and disease activity213–217.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [217]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
Henn, V., Slupsky, J. R., Gräfe, M., Anagnostopoulos, I., Förster, R., Müller-Berghaus, G., & Kroczek, R. A. (1998) · Nature · doi:10.1038/35393 · Cited by 2,078
Microparticles in Hemostasis and Thrombosis
Owens, A. P., & Mackman, N. (2011) · Circulation Research · doi:10.1161/circresaha.110.233056 · Cited by 835
Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60128-8 · Cited by 752
Schiraldi, M., Raucci, A., Muñoz, L. M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., De Marchis, F., Pedotti, M., Bachi, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111739 · Cited by 676
The role of defective clearance of apoptotic cells in systemic autoimmunity
Muñoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A., & Herrmann, M. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.46 · Cited by 627
Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity
Sisirak, V., Sally, B., D’Agati, V., Martinez-Ortiz, W., Özçakar, Z. B., David, J., Rashidfarrokhi, A., Yeste, A., Panea, C., Chida, A. S., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.034 · Cited by 450
LACROIX, R., ROBERT, S., PONCELET, P., KASTHURI, R. S., KEY, N. S., & DIGNAT‐GEORGE, F. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04047.x · Cited by 351
The role of microparticles in the pathogenesis of rheumatic diseases
Beyer, C., & Pisetsky, D. S. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.229 · Cited by 324
Self-citation
Cited by
Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases
Duvvuri, B., & Lood, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00502 · Cited by 282
“MPs, in particular if released from activated platelets, could also be the source of cf-mtDNA (57, 59, 60).”
BackgroundPlatelet Extracellular Vesicles: Beyond the Blood
Puhm, F., Boilard, E., & Machlus, K. R. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.314644 · Cited by 250
Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation
French, S. L., Butov, K. R., Allaeys, I., Canas, J., Morad, G., Davenport, P. E., Laroche, A., Trubina, N. M., Italiano, J. E., Moses, M. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001758 · Cited by 118
Ortega, A., Martínez-Arroyo, O., Forner, M. J., & Cortés, R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010003 · Cited by 117
“Additionally, a deeper phenotypic analysis of MP from SLE showed that MP were more abundant in these patients and were associated with declining renal function [80].”
BackgroundGlobal requirements for manufacturing and validation of clinical grade extracellular vesicles
Thakur, A., & Rai, D. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100278 · Cited by 132
“Thus, extracting and modifying them for therapeutic purposes can be achieved easily [111 – 116].”
Pathogenic cellular and molecular mediators in lupus nephritis
Mohan, C., Zhang, T., & Putterman, C. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00722-z · Cited by 105
Extracellular vesicles as potential biomarkers and therapeutic approaches in autoimmune diseases
Xu, K., Liu, Q., Wu, K., Liu, L., Zhao, M., Yang, H., Wang, X., & Wang, W. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02609-0 · Cited by 107
The role of mitochondria in rheumatic diseases
Becker, Y. L. C., Duvvuri, B., Fortin, P. R., Lood, C., & Boilard, E. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00834-z · Cited by 81
Different sourced extracellular vesicles and their potential applications in clinical treatments
Bahmani, L., & Ullah, M. (2022) · Cells · doi:10.3390/cells11131989 · Cited by 83
Burbano, C., Villar-Vesga, J., Orejuela-Erazo, J., Muñoz, C., Vanegas-García, A. L., Vásquez, G. M., Rojas, M., & Castaño, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00322 · Cited by 82
Tsai, C., Hsieh, S., Liu, C., Lu, C.-S., Wu, C.-H., Liao, H., Chen, M., Li, K., Shen, C., Kuo, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063119 · Cited by 96
Rother, N., Pieterse, E., Lubbers, J., Hilbrands, L. B., & van der Vlag, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01136 · Cited by 77
Becker, Y., Loignon, R.-C., Julien, A.-S., Marcoux, G., Allaeys, I., Lévesque, T., Rollet-Labelle, E., Benk-Fortin, H., Cloutier, N., Melki, I., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40900-3 · Cited by 75
Extracellular vesicles in Inflammatory Skin Disorders: from Pathophysiology to Treatment
Shao, S., Fang, H., Li, Q., & Wang, G. (2020) · Theranostics · doi:10.7150/thno.45488 · Cited by 80
“As early studies reported, the total number of EVs and IgG-positive EVs were increased in the plasma of SLE patients [18, 179], and their high levels were positively correlated with anti-DNA levels, suggesting that these EVs could represent an important source of immune complexes in SLE [180].”
BackgroundPost-Translational Modification of HMGB1 Disulfide Bonds in Stimulating and Inhibiting Inflammation
Andersson, J., Tracey, K. J., & Yang, H. (2021) · Cells · doi:10.3390/cells10123323 · Cited by 82
“A second route for HMGB1 to exit cells is via its expression on the surface of microparticles derived from activated platelets [25,26].”
BackgroundMobarrez, F., Fuzzi, E., Gunnarsson, I., Larsson, A., Eketjäll, S., Pisetsky, D. S., & Svenungsson, E. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.05.003 · Cited by 68
Self-citationEvolving story of autoantibodies in systemic lupus erythematosus
Pisetsky, D. S. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102356 · Cited by 78
Self-citationMoonlighting chromatin: when DNA escapes nuclear control
Singh, J., Boettcher, M., Dölling, M., Heuer, A., Hohberger, B., Leppkes, M., Naschberger, E., Schapher, M., Schauer, C., Schoen, J., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01124-1 · Cited by 71
Self-citationScherlinger, M., Guillotin, V., Douchet, I., Vacher, P., Boizard-Moracchini, A., Guégan, J., Garreau, A., Merillon, N., Vermorel, A., Ribeiro, E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi4994 · Cited by 66
Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1
Gorgulho, C. M., Romagnoli, G. G., Bharthi, R., & Lotze, M. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01561 · Cited by 57
“Dendritic cells (DCs) preferentially present antigens from NETotic neutrophils (60) and HMGB1 present in NETs released by neutrophils from pedriatic SLE patients up-regulate type I interferon production by tissue plasmacytoid DCs, which Frontiers in Immunology | www.frontiersin.org 3 July 2019 | Volume 10 | Article 15…”
BackgroundInfluentialBurbano, C., Villar-Vesga, J., Vásquez, G. M., Muñoz‐Vahos, C. H., Rojas, M., & Castaño, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02058 · Cited by 59
“MP from patients with RA and SLE reportedly contain proinflammatory components and autoantigens such as citrullinated peptides, high-mobility group protein 1 (HMGB1), and nucleic acids (4, 8).”
BackgroundEndothelial function and endothelial progenitor cells in systemic lupus erythematosus
Mak, A., & Chan, J. K. Y. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00770-y · Cited by 57
Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects
Soni, C., & Reizis, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01601 · Cited by 58
HMGB1/IL-1β complexes in plasma microvesicles modulate immune responses to burn injury
Coleman, L. G., Maile, R., Jones, S., Cairns, B. A., & Crews, F. T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195335 · Cited by 56
Misunderstandings Between Platelets and Neutrophils Build in Chronic Inflammation
Ramirez, G. A., Manfredi, A. A., & Maugeri, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02491 · Cited by 50
“However, PDμP also accumulate during active SLE (233, 234) and might impact on inflammation and hemostasis (34, 234).”
BackgroundMicroparticles as autoantigens in systemic lupus erythematosus
Mobarrez, F., Svenungsson, E., & Pisetsky, D. S. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13010 · Cited by 47
“In SLE, PS‐ particles appear to constitute a much larger proportion of MPs as compared to controls.(40,55) As discussed above, PS‐ particles may preferentially remain in the circulation, as PS is an important signal for removal of particles by the immune system.”
BackgroundResultInfluentialSelf-citationBurbano, C., Gómez-Puerta, J. A., Muñoz‐Vahos, C. H., Vanegas-García, A. L., Rojas, M., Vásquez, G. M., & Castaño, D. (2018) · European Journal of Immunology · doi:10.1002/eji.201847747 · Cited by 45
Platelet-Derived Extracellular Vesicles
Gąsecka, A., Nieuwland, R., & Siljander, P. R. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00022-9 · Cited by 48
Willis, M. L., Mahung, C., Wallet, S. M., Barnett, A., Cairns, B. A., Coleman, L. G., & Maile, R. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mia0321-150rr · Cited by 43
Implication of Platelets in Immuno-Thrombosis and Thrombo-Inflammation
Zaid, Y., & Merhi, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.863846 · Cited by 45
Platelet extracellular vesicles in COVID-19: Potential markers and makers
Puhm, F., Flamand, L., & Boilard, É. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0221-100r · Cited by 42
The Role of Platelet-Derived Extracellular Vesicles in Immune-Mediated Thrombosis
Eustes, A. S., & Dayal, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147837 · Cited by 45
“Smaller PEVs in lupus were determined to have decreased mitochondrial proteins but increased glycolytic and apoptotic proteins, including annexin V, CD40 ligand, and galectin-3 binding protein G3BP [78,158,160].”
BackgroundWigren, M., Svenungsson, E., Mattisson, I. Y., Gustafsson, J. T., Gunnarsson, I., Zickert, A., Elvin, K., Jensen‐Urstad, K., Bengtsson, A. A., Gullstrand, B., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.022 · Cited by 38
Self-citationSvenungsson, E., Gustafsson, J. T., Grosso, G., Rossides, M., Gunnarsson, I., Jensen‐Urstad, K., Larsson, A. O., Ekdahl, K. N., Nilsson, B., Bengtsson, A. A., et al. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa092 · Cited by 35
Self-citationThe central role of nucleic acids in the pathogenesis of systemic lupus erythematosus
Pisetsky, D. S. (2019) · F1000Research · doi:10.12688/f1000research.17959.1 · Cited by 33
Self-citationDNA-nanoparticle interactions: Formation of a DNA corona and its effects on a protein corona
Griffith, D. M., Jayaram, D. T., Spencer, D. M., Pisetsky, D. S., & Payne, C. K. (2020) · Biointerphases · doi:10.1116/6.0000439 · Cited by 35
Self-citationMazzariol, M., Camussi, G., & Brizzi, M. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084194 · Cited by 31
“EV were found increased in SLE [51,52], or decreased compared to healthy controls [53].”
BackgroundHMGB1 is a critical molecule in the pathogenesis of Gram-negative sepsis
Andersson, J., & Yang, H. (2022) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2022.02.001 · Cited by 31
“[36] Mobarrez F, Vikerfors A, Gustafsson JT, Gunnarsson I, Zickert A, Larsson A, et al.”
BackgroundWong, C., Stoilova, I., Gazeau, F., Herbeuval, J., & Fourniols, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1355845 · Cited by 30
Potential Diagnostic Approaches for Prediction of Therapeutic Responses in Immune Thrombocytopenia
Jolink, A.-T. C., Nelson, V. S., Schipperus, M. R., Amini, S. N., Vidarsson, G., van der Schoot, C. E., Porcelijn, L., de Haas, M., & Kapur, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153403 · Cited by 27
Extracellular Vesicles as Potential Theranostic Platforms for Skin Diseases and Aging
Kim, H., Lee, J. W., Han, G., Kim, K., Yang, Y., & Kim, S. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050760 · Cited by 25
Leleu, D., Levionnois, É., Laurent, P., Lazaro, E., Richez, C., Duffau, P., Blanco, P., Sisirak, V., Contin‐Bordes, C., & Truchetet, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.532177 · Cited by 27
The pathobiology of platelet and megakaryocyte extracellular vesicles: A (c)lot has changed
Stone, A. P., Nikols, E., Freire, D., & Machlus, K. R. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15750 · Cited by 26
Surface complement C3 fragments and cellular binding of microparticles in patients with SLE
Winberg, L. K., Nielsen, C. H., & Jacobsen, S. (2017) · Lupus Science & Medicine · doi:10.1136/lupus-2016-000193 · Cited by 26
Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus
Brilland, B., Scherlinger, M., Khoryati, L., Goret, J., Duffau, P., Lazaro, E., Charrier, M., Guillotin, V., Richez, C., & Blanco, P. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08744-x · Cited by 26
Antovič, A., Mobarrez, F., Manojlović, M., Soutari, N. M. H., Baggemar, V. D. P., Nordin, A., Bruchfeld, A. N., Vojinović, J., & Gunnarsson, I. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.181347 · Cited by 23
“Although the presence of bound complement components C1q, C3b and C4b on cell-derived MPs previously were investigated in patients with other autoimmune disorders like systemic lupus erythematosus and rheumatoid arthritis (32-34), this has not been the case in patients with AAVs.”
BackgroundSelf-citationThe Role of Platelet–Neutrophil Interactions in Driving Autoimmune Diseases
Liu, Q., Zhu, W., Wen, X., & Da, Y. (2025) · Immunology · doi:10.1111/imm.13901 · Cited by 22
“In parallel, platelet activation also leads to the generation of PMPs, which are consistently elevated in SLE and correlate with disease activity, especially in patients with active renal involvement [129].”
Bergen, K., Mobarrez, F., Jörneskog, G., Wallén, H., & Tehrani, S. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.10.026 · Cited by 20
Self-citationÁlvarez, K. V., Villar-Vesga, J., Ortíz-Reyes, B., Vanegas-García, A. L., Castaño, D., Rojas, M., & Vásquez, G. M. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05815 · Cited by 18
Microparticles in Autoimmunity: Cause or Consequence of Disease?
Rother, N., Yanginlar, C., Pieterse, E., Hilbrands, L. B., & van der Vlag, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822995 · Cited by 20
Mechanisms of vascular comorbidity in autoimmune diseases
Nagy, G., Németh, N., & Buzás, E. I. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000483 · Cited by 16
Platelet-Released Extracellular Vesicle Characteristics Differ in Chronic and in Acute Heart Disease
Vilella-Figuerola, A., Cordero, A., Mirabet, S., Muñoz‐García, N., Suades, R., Padró, T., & Badimón, L. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0043-57017 · Cited by 15
Platelets are a major player and represent a therapeutic opportunity in systemic lupus erythematosus
Robert, M., & Scherlinger, M. (2023) · Joint Bone Spine · doi:10.1016/j.jbspin.2023.105622 · Cited by 14
Manzano, E. M., Bello, I. F., Sanz, R. J., Marhuenda, Á. R., López‐Longo, F. J., Acuña, P., Román, M. T. Á., Jiménez‐Yuste, V., & Butta, N. V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103297 · Cited by 12
“These results might be explained because MPs from patients with SLE are predominantly PS-negative [37].”
BackgroundThe Autoantigen Repertoire and the Microbial RNP World
Williams, S. G., & Wolin, S. L. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.02.003 · Cited by 12
Lam, K. C. K., Lam, M. K. N., Chim, C. S., Chan, G., & Li, J. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0420-067r · Cited by 12
Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!
Colic, J., Matucci‐Cerinic, M., Guiducci, S., & DAMJANOV, N. S. (2019) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319857356 · Cited by 13
Extracellular vesicles in laboratory medicine: a review and outlook
Wang, X., Liu, M., Zhao, M., Shen, H., Jin, Q., Rao, D., & Huang, D. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1709461 · Cited by 11
Richter, P., Cardoneanu, A., Rezuș, C., Burlui, A., & Rezuş, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012604 · Cited by 11
Phosphatidylserine Exposing Extracellular Vesicles in Pre-eclamptic Patients
Lalic‐Cosic, S., Dopsaj, V., Kovac, M. K., Mandić, V., Miković, Ž., Mobarrez, F., & Antovič, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.761453 · Cited by 10
Self-citationPlatelet-Derived Extracellular Vesicles as Lipid Carriers in Severe Allergic Inflammation
Couto-Rodriguez, A., Villaseñor, A., Pablo‐Torres, C., Obeso, D., Rey-Stolle, F., Peinado, H., Bueno, J. L., Reaño-Martos, M., Cadarso, A. I., Gómez‐Casado, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612714 · Cited by 9
“rheumatoid arthritis [28], multiple sclerosis [29], lupus erythematosus [30], and asthma [31], where increased particle numbers were described in patients with these diseases.”
BackgroundMicroparticles - culprits in the pathogenesis of systemic lupus erythematosus?
Rasmussen, N. S., & Jacobsen, S. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1474100 · Cited by 9
Suades, R., Vilella-Figuerola, A., Padró, T., Mirabet, S., & Badimón, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411824 · Cited by 8
“This hypothesis was further supported by the findings of two studies in SLE and APS, where PS−-EVs were the main type of EVs found in patients but not in controls [31,34].”
BackgroundResultThe role of microparticles in the pathogenesis of SLE: a new look at an old paradigm
Pisetsky, D. S. (2017) · Lupus Science & Medicine · doi:10.1136/lupus-2017-000220 · Cited by 8
Self-citationOrganellomics: AI-driven deep organellar phenotyping reveals novel ALS mechanisms in human neuronsPreprint
Krispin, S., van Zuiden, W., Danino, Y. M., Rudberg, N., Molitor, L., Abarbanel, B., Aviram, G., Wolf, G., Bar, C., Siani, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.31.572110 · Cited by 10
Myeloid Responses to Extracellular Vesicles in Health and Disease
Makhijani, P., & McGaha, T. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818538 · Cited by 7
“Though finding EV biomarkers that differentiate related disease states have proven difficult, this line of investigation may be useful for both cancer and systemic autoimmune conditions (114, 115).”
BackgroundMartin, N., Tu, X., Egan, A. J., & Stover, C. M. (2020) · Medicina · doi:10.3390/medicina56100533 · Cited by 6
“They are found elevated at significant circulating levels in the blood of patients with SLE [7] and can act as platforms for the assembly of immune complexes and sites of complement activation.”
BackgroundLosada, P. X., Serrato, L. M., Zapata, A. M. D., Vanegas-García, A. L., Muñoz, C. H., Rodríguez, D., Diaz, J. C., Pineda, R., Lopez, M. R., & Vásquez, G. M. (2024) · Lupus Science & Medicine · doi:10.1136/lupus-2024-001243 · Cited by 6
Platelet-Derived Extracellular Vesicles in Arterial Thrombosis
Harper, M. T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-1443-2_17 · Cited by 6
Anti-DNA-IgM Favors the Detection of NET-Associated Extracellular DNA
Wang, H., Stehr, A. M., Singh, J., Zlatar, L., Hartmann, A., Evert, K., Naschberger, E., von Stillfried, S. F., Boor, P., Munoz, L. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044101 · Cited by 5
“For instance, it may gain antigenic activity and bind to serum components including autoantibodies of patients with Systemic lupus erythematosus (SLE); this may generate massive amounts of pathogenic immune complexes [4,5].”
BackgroundSevere Allergy as a Chronic Inflammatory Condition From a Systems Biology Perspective
Dolset, M. I. D., Pablo‐Torres, C., Contreras, N., Couto-Rodriguez, A., Escolar‐Peña, A., Graña‐Castro, O., Izquierdo, E., López‐Rodríguez, J. C., Macías‐Camero, A., Pérez‐Gordo, M., et al. (2024) · Clinical & Experimental Allergy · doi:10.1111/cea.14517 · Cited by 7
Cytoplasmic DNA sensing boosts CD4+ T cell metabolism for inflammatory induction
Ye, J., Fu, J., Hou, H., Wang, Y., Deng, W., Hao, S., Pei, Y., Xu, J., Zheng, M., & Xiao, Y. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad021 · Cited by 4
Cellular Microvesicles in the Blood of Patients with Systemic Lupus Erythematosus
Nevzorova, T. A., Evtugina, N. G., & Игоревич, Л. Р. (2017) · BioNanoScience · doi:10.1007/s12668-017-0478-z · Cited by 3
“It is noteworthy that the difference in MV content was earlier established for phosphatidylserineexpressing MVs, while in our study, MVs were identified using a calcein dye [11] without segregation into phosphatidylserine-positive and phosphatidylserine-negative particles [13].”
ResultRivera-Rivas, J. J., & Czuprynski, C. J. (2021) · Veterinary Microbiology · doi:10.1016/j.vetmic.2021.109280 · Cited by 2
Bratseth, V., Nordeng, J., Helseth, R., Solheim, S., Åkra, S., Arnesen, H., Chiva‐Blanch, G., & Seljeflot, I. (2022) · Biomedicines · doi:10.3390/biomedicines10092196 · Cited by 2
“Our results are consistent with previous reports demonstrating AV− MVs in patients with procoagulant conditions, such as STEMI, systemic lupus erythematosus (SLE), and type 1 diabetes mellitus [36,39,43].”
ResultLarsen, M. L., Demir, F., Langkilde, H. Z., Linge, P., Grenmyr, E., Hauge, E., Voss, A., Rinschen, M. M., Bengtsson, A. A., Larsen, J. B., et al. (2026) · Journal of Autoimmunity · doi:10.1016/j.jaut.2026.103615 · Cited by 1
Antihistone and antispliceosome antibodies
Satoh, M., Fritzler, M. J., & Chan, E. K. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00028-3 · Cited by 1
Caruso, I., Caruso, E. M., Santandrea, S., Montrone, F., Sarzi‐Puttini, P., & Cazzola, M. (2018) · Translational Medicine Communications · doi:10.1186/s41231-018-0022-3
“Although microparticles have been described in systemic lupus erythematous [17, 18], they appear to be unrelated to the microcomplexes described herein because they are too large (0.”
BackgroundCharacterisation of Cholesterolcontaining Microparticles in Autoimmunity
Hu, S. S. (2019) · Arrow - TU Dublin (Technological University Dublin) · doi:10.21427/rqce-bh11
“08 Medicine Mycophenolate 3 Prednisolone 3 Plaquenil 6 Azathioprine 1 Valacylovir 1 RA Patient Cohort RF (IU/ml)(median[min-max]) 124 (0-5350) CCP (U/ml) (median[min-max]) 219 (1-600) ESR (mm/hr) (median[min-max]) 14.”
BackgroundMicroparticles in hemophilia - friend or foe? : to improve hemostasis or to induce atherothrombosis?
Zong, Y. (2020) · Figshare
Pisetsky, D. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00050-5
Self-citationPopescu, N. I., Coggeshall, K. M., & Lupu, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00131-9
Verma, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9777051/v1
Role of dendritic cell in systemic lupus erythematosus pathophysiology
Tchen, J., Huot-Marchand, S., Vasilakou, A., Santa, P., Roubertie, A., Loizon, S., Duluc, D., Leibler, C., Richez, C., Blanco, P., et al. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33957-8.00021-4
Platelets in systemic lupus erythematosus: from hemostatic allies to pathogenic drivers
Wu, Y., Yang, Z., Huang, S., Bao, J., Fan, Y., & Xie, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778274
“PMPs and PMP-associated cargoes are particularly attractive biomarkers because they can carry phosphatidylserine, platelet glycoproteins, mitochondrial DNA, oxidized mtDNA, immuno-globulins, acetylated histones, and complement-related molecules (4, 99).”
Metadata
- Authors
- Mobarrez, F., Vikerfors, A., Gustafsson, J. T., Gunnarsson, I., Zickert, A., Larsson, A., Pisetsky, D. S., Wallén, H., & Svenungsson, E.
- Affiliations
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Duke Medical Center (US)
- Danderyds sjukhus (SE)
- Corresponding author
- Mobarrez, Fariborz
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-10-25
- Volume
- 6
- Issue
- 1
- Pages
- 36025-36025
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5078765
- OpenAlex
- W2534182712
- Cited by
- 85
- References
- 56
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 14 · 2019: 15 · 2018: 8 · 2017: 5
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- Funders
- Hjärt-Lungfonden
- Karolinska Institutet
- Stockholms Läns Landsting
- Vetenskapsrådet
- Svenska Läkaresällskapet
- Reumatikerförbundet
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- systemic lupus erythematosus, microparticles, phosphatidylserine, cell death, immune complexes, autoantibodies, liquid biopsy, renal function, disease activity, smoking, sex differences
- MeSH terms
- Antigen-Antibody Complex, Autoantibodies, Autoantigens, Blood Platelets, Cross-Sectional Studies, Female, Flow Cytometry, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Thromboplastin, Biomarkers, Vascular Cell Adhesion Molecule-1, CD40 Ligand, HMGB1 Protein, Cell-Derived Microparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.